Regenxbio

RegenXBio cashes in $250M worth of payments for Zolgensma, 2 other gene therapies
Fierce Biotech
Tue, 05/20/25 - 10:18 am
Regenxbio
Novartis
Zolgensma
gene therapy
spinal muscular atrophy
FDA accepts Regenxbio’s application for MPS II gene therapy
World Pharmaceuticals Frontiers
Wed, 05/14/25 - 11:15 am
Regenxbio
FDA
RGX-121
Hunter Syndrome
gene therapy
REGENXBIO reports promising gene therapy trial results
Investing.com
Wed, 03/19/25 - 11:12 pm
Regenxbio
DMD
RGX-202
RegenXBio sells Hunter syndrome gene therapy's U.S., Asia commercial rights for $110M upfront
Fierce Biotech
Tue, 01/14/25 - 09:59 am
Regenxbio
Hunter Syndrome
gene therapy
Asia
RegenxBio touts positive data for rare disease drug RGX-121
Clinical Trials Arena
Wed, 09/4/24 - 11:20 am
Regenxbio
RGX-121
clinical trials
Hunter Syndrome
Regenxbio CEO to step down after 15 years
BioPharma Dive
Wed, 06/12/24 - 11:23 pm
Regenxbio
Pharma CEOs
gene therapy
Kenneth Mills
AbbVie and Regenxbio’s ‘multibillion-dollar opportunity’ in vision loss gene therapy
Pharma Voice
Wed, 04/24/24 - 08:42 am
Regenxbio
AbbVie
gene therapy
ABBV-RGX-314
wet age-related macular degeneration
diabetic retinopathy
Regenxbio data suggest ‘niche’ in Duchenne gene therapy
BioPharma Dive
Thu, 03/7/24 - 11:05 am
Regenxbio
Duchenne Muscular Dystrophy
DMD
RGX-202
Sarepta Therapeutics
Elevidys
Regenxbio unveils positive data from diabetic retinopathy therapy trial
Clinical Trials Arena
Mon, 11/6/23 - 11:27 am
Regenxbio
clinical trials
ABBV-RGX-314
diabetic retinopathy
Chasing Pfizer and Roche, Regenxbio benefits from FDA boost for DMD gene therapy
Fierce Biotech
Tue, 04/11/23 - 11:32 am
Regenxbio
adeno-associated viruses
Duchenne Muscular Dystrophy
FDA
Duchenne muscular dystrophy’s progress so far in 2023
Clinical Trials Arena
Wed, 02/22/23 - 10:00 am
Duchenne Muscular Dystrophy
DMD
Santhera Pharmaceuticals
ReveraGen
vamorolone
Regenxbio
RGX-202
RegenXBio gets FDA support for Hunter syndrome gene therapy's accelerated review filing—in 2024
Fierce Biotech
Wed, 08/3/22 - 10:58 am
Regenxbio
Hunter Syndrome
RGX-121
accelerated approval
FDA
Amgen, GSK, Regenxbio and others urge SCOTUS to review 'damaging' decision on biomedical patents
Endpoints
Tue, 07/19/22 - 10:01 pm
Amgen
GSK
Regenxbio
Supreme Court
innovation
patents
Regenxbio expands MPS I gene therapy trial after first look at data
Pharmaforum
Fri, 02/11/22 - 10:28 am
Regenxbio
gene therapy
Hurler Syndrome
RGX-111
Why AbbVie Just Made a $1.8 Billion Gene Therapy Deal
Motley Fool
Sat, 09/25/21 - 11:00 pm
AbbVie
Regenxbio
gene therapy
wet age-related macular degeneration
Zolgensma patent spat brews between Novartis and Regenxbio as top Novartis gene therapy exec departs
Endpoints
Mon, 09/20/21 - 11:15 am
Regenxbio
gene therapy
patents
Novartis
Zolgensma
SMA
AbbVie, Regenxbio enter deal to develop retinal disease therapy
Reuters
Mon, 09/13/21 - 10:29 am
AbbVie
Regenxbio
RGX-314
gene therapy
retinal disease
Sarepta faces another gene therapy hiccup as Regenxbio sues over Jim Wilson's patent
Endpoints
Thu, 09/17/20 - 10:40 am
Sarepta Therapeutics
gene therapy
Regenxbio
Duchenne Muscular Dystrophy
Regenxbio sues FDA over gene therapy clinical hold
Fierce Biotech
Mon, 11/11/19 - 11:02 am
Regenxbio
FDA
clinical hold
gene therapy
clinical trials
Big Pharma Has Mad Love For These 2 Biotechs
Motley Fool
Fri, 10/11/19 - 10:41 pm
Big Pharma
biotechs
Regenxbio
Denali Therapeutics

Pages